Yarrow Bioscience, Inc. Common Stock
YARW
45 hedge funds and large institutions have $68.4M invested in Yarrow Bioscience, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
7% more funds holding
Funds holding: 42 → 45 (+3)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less capital invested
Capital invested by funds: $161M → $68.4M (-$92.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.6M |
| 2 |
First Manhattan
New York
|
+$2.35M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.41M |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$1.07M |
| 5 |
JP Morgan Chase
New York
|
+$739K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.66M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.25M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$2.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.86M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.03M |
YARW Hedge Fund Activity: Q4 2018 in Review
45 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new YARW positions and 10 closed out — a net gain of 3 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.
- 45 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2018, up from 42 in Q3 2018.
- Funds reported $68.4M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2018, down 57% quarter-over-quarter.
- 13 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2018 and 10 closed out, a net change of +3 holders.
- The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
- The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.
Based on aggregated 13F filings for Q4 2018.